Trexquant Investment LP Raises Stock Position in 10x Genomics $TXG

Key Points

• Trexquant Investment LP significantly increased its stake in 10x Genomics by 91.8%, now holding approximately 1,140,288 shares worth about $9.95 million.
• 10x Genomics reported earnings of $0.28 per share, surpassing analysts' expectations, with revenue of $172.91 million for the quarter, indicating a 12.9% year-over-year growth.
• Institutional investors collectively own 84.68% of 10x Genomics, reflecting strong interest from the investment community amid varying analyst ratings, including six buy and six hold ratings.

Trexquant Investment LP lifted its holdings in 10x Genomics (NASDAQ:TXG - Free Report) by 91.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,140,288 shares of the company's stock after buying an additional 545,677 shares during the period. Trexquant Investment LP owned approximately 0.93% of 10x Genomics worth $9,955,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the company. GAMMA Investing LLC raised its stake in 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after purchasing an additional 1,614 shares during the period. Xponance Inc. raised its stake in 10x Genomics by 17.4% during the first quarter. Xponance Inc. now owns 12,010 shares of the company's stock worth $105,000 after purchasing an additional 1,778 shares during the period. GF Fund Management CO. LTD. purchased a new position in 10x Genomics during the fourth quarter worth about $32,000. AlphaQuest LLC raised its stake in 10x Genomics by 8.3% during the first quarter. AlphaQuest LLC now owns 29,459 shares of the company's stock worth $257,000 after purchasing an additional 2,258 shares during the period. Finally, Signaturefd LLC raised its stake in 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company's stock worth $37,000 after purchasing an additional 2,409 shares during the period. 84.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have commented on TXG. Canaccord Genuity Group set a $16.00 target price on shares of 10x Genomics in a research note on Monday, August 11th. Deutsche Bank Aktiengesellschaft set a $14.00 price target on shares of 10x Genomics and gave the company a "hold" rating in a research report on Friday, August 8th. UBS Group lifted their price target on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a research report on Friday, August 8th. Wall Street Zen upgraded shares of 10x Genomics from a "hold" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Stephens reiterated an "overweight" rating and set a $14.00 price target on shares of 10x Genomics in a research report on Thursday, May 15th. Six investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and a consensus price target of $13.54.

10x Genomics Price Performance

Shares of TXG stock traded down $0.27 during trading on Monday, reaching $14.01. The company's stock had a trading volume of 1,566,109 shares, compared to its average volume of 3,022,419. The company has a market capitalization of $1.74 billion, a price-to-earnings ratio of -20.01 and a beta of 2.00. The stock's 50-day moving average price is $12.98 and its 200 day moving average price is $10.70. 10x Genomics has a 1-year low of $6.78 and a 1-year high of $24.76.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping the consensus estimate of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The company had revenue of $172.91 million during the quarter, compared to analysts' expectations of $139.36 million. During the same quarter in the previous year, the business posted ($0.32) EPS. The firm's revenue was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. On average, sell-side analysts anticipate that 10x Genomics will post -1.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the transaction, the chief executive officer owned 945,892 shares in the company, valued at $13,043,850.68. The trade was a 0.98% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam Taich sold 22,315 shares of the business's stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $307,723.85. Following the transaction, the chief financial officer owned 309,273 shares of the company's stock, valued at $4,264,874.67. This trade represents a 6.73% decrease in their position. The disclosure for this sale can be found here. Insiders sold 39,149 shares of company stock worth $539,865 in the last 90 days. Corporate insiders own 10.03% of the company's stock.

10x Genomics Company Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.